Skip to main content
DMIIDrugs Made In America AcquisitiSell4.0·$10.09+0.00%
SellModerate Confidence
Investment thesis

DMII screens as a low-quality, expensive shell entity with no identifiable edge; tentative volume accumulation is the only supportive signal against an otherwise AVOID-rated setup.

Thesis pillars

  • Expensive Valuation FlagStable
  • Quality Floor BreachStable
  • Tentative Momentum AccumulationStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Drugs Made In America Acquisiti (DMII) Stock Analysis

Range Bound setup

SellQualityShortModerate Confidence

Financial Services · Shell Companies

Sell if holding. Engine safety override at $10.09: Quality below floor (1.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: Below-average business quality; Rich valuation.

We are a blank check company incorporated in the Cayman Islands as an exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. We... Read more

$10.09-1.9% A.UpsideScore 4.0/10#23 of 27 Shell Companies
QualityF-score0 / 9FCF yield
Stop $10.05Target $9.90(resistance)A.R:R 0.0:1

Sell if holding. Engine safety override at $10.09: Quality below floor (1.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: Below-average business quality; Rich valuation. Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 4.0/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.

Thesis

Rewards
No bull case signals
Risks
Quality below floor (1.1 < 4.0)

Key Metrics

P/E (TTM)72.1
P/E (Fwd)
Mkt Cap$643M
EV/EBITDA
Profit Mgn0.0%
ROE
Rev Growth
Beta
DividendNone
Rating analysts

Quality Signals

Piotroski F0/9

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Piotroski F
0.0
Current Ratio
2.1
Moat
4.5
No competitive moatWeak Piotroski F-Score: 0/9Quality concerns

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Pe
1.4
Expensive valuation
Low model confidence on this dimension (20%).
GatesMomentum 5.2<5.5 (soft — BUY_NOW allowed but watch)A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Momentum 5.2>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
53 · Neutral
20D MA 50D MA 200D MASupport $10.05Resistance $10.10

Price Targets

$10
$10
A.Upside-1.9%
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.1 < 4.0)

Earnings

We could not retrieve earnings history for DMII.
The company may be recently listed, pre-revenue, or its beat/miss record wasn't available from our source this run. Earnings signals feed the Growth and Catalyst score dimensions — absence here doesn't affect other dimensions.

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is DMII stock a buy right now?

Sell if holding. Engine safety override at $10.09: Quality below floor (1.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: Below-average business quality; Rich valuation. Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $10.05. Score 4.0/10, moderate confidence.

What is the DMII stock price target?

Take-profit target: $9.90 (-1.9% upside). Prior stop was $10.05. Stop-loss: $10.05.

What are the risks of investing in DMII?

Quality below floor (1.1 < 4.0).

Is DMII overvalued or undervalued?

Drugs Made In America Acquisiti trades at a P/E of 72.1 (forward N/A). TrendMatrix value score: 1.4/10. Verdict: Sell.

0
What does Drugs Made In America Acquisiti do?We are a blank check company incorporated in the Cayman Islands as an exempted company for the purpose of effecting a...

We are a blank check company incorporated in the Cayman Islands as an exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. We have neither engaged in any operations nor generated any revenue to date.

Related stocks: KBON (Karbon Capital Partners Corp.) · KRSP (Rice Acquisition Corporation 3) · CXII (Churchill Capital Corp XII Class A Ordinary Shares) · BCAR (D. Boral ARC Acquisition I Corp) · MBVI (M3-Brigade Acquisition VI Corp.)
Home Stocks DMII

Latest news

No recent news